📊 PMVP Key Takeaways
Is PMV Pharmaceuticals, Inc. (PMVP) a Good Investment?
PMV Pharmaceuticals exhibits severe fundamental deterioration with revenue collapsing 40.5% YoY to just $6.3M while operating losses reach $86.2M, indicating a critical commercial failure. Negative free cash flow of $73.6M annually against only $38M cash creates an estimated 6-month runway, necessitating immediate capital raise or strategic alternatives. The company is fundamentally unprofitable and unsustainable in its current state despite a balance sheet that provides only a temporary buffer.
Why Buy PMV Pharmaceuticals, Inc. Stock? PMVP Key Strengths
- Strong balance sheet with $104.7M equity and minimal debt provides strategic flexibility
- Adequate short-term liquidity with $38M cash and 10x current ratio enables near-term operations
- Low capital intensity with minimal capex requirements reduces cash burn pressure
PMVP Stock Risks: PMV Pharmaceuticals, Inc. Investment Risks
- Revenue collapsed 40.5% YoY to $6.3M indicating complete commercial failure of core products
- Operating losses of $86.2M on minimal revenue with negative $73.6M annual FCF create 6-month cash runway
- Deteriorating EPS trend (-29.8% YoY) shows worsening losses; dilution or bankruptcy likely without rescue capital
Key Metrics to Watch
- Cash runway and timing of next capital raise or strategic transaction
- Revenue stabilization and evidence of new product commercialization success
- Operating burn rate trajectory and path to breakeven viability
PMV Pharmaceuticals, Inc. (PMVP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.09x current ratio provides a solid financial cushion.
PMVP Profit Margin, ROE & Profitability Analysis
PMVP vs Healthcare Sector: How PMV Pharmaceuticals, Inc. Compares
How PMV Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PMV Pharmaceuticals, Inc. Stock Overvalued? PMVP Valuation Analysis 2026
Based on fundamental analysis, PMV Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PMV Pharmaceuticals, Inc. Balance Sheet: PMVP Debt, Cash & Liquidity
PMVP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PMV Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.44 indicates the company is currently unprofitable.
PMVP Revenue Growth, EPS Growth & YoY Performance
PMV Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
PMVP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PMV Pharmaceuticals, Inc. (CIK: 0001699382)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PMVP
What is the AI rating for PMVP?
PMV Pharmaceuticals, Inc. (PMVP) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PMVP's key strengths?
Claude: Strong balance sheet with $104.7M equity and minimal debt provides strategic flexibility. Adequate short-term liquidity with $38M cash and 10x current ratio enables near-term operations.
What are the risks of investing in PMVP?
Claude: Revenue collapsed 40.5% YoY to $6.3M indicating complete commercial failure of core products. Operating losses of $86.2M on minimal revenue with negative $73.6M annual FCF create 6-month cash runway.
What is PMVP's revenue and growth?
PMV Pharmaceuticals, Inc. reported revenue of $6.3M.
Does PMVP pay dividends?
PMV Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find PMVP SEC filings?
Official SEC filings for PMV Pharmaceuticals, Inc. (CIK: 0001699382) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PMVP's EPS?
PMV Pharmaceuticals, Inc. has a diluted EPS of $-1.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PMVP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, PMV Pharmaceuticals, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PMVP stock overvalued or undervalued?
Valuation metrics for PMVP: ROE of -74.2% (sector avg: 15%), net margin of -1,226.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PMVP stock in 2026?
Our dual AI analysis gives PMV Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PMVP's free cash flow?
PMV Pharmaceuticals, Inc.'s operating cash flow is $-73.6M, with capital expenditures of $29.0K. FCF margin is -1,161.5%.
How does PMVP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,226.8% (avg: 12%), ROE -74.2% (avg: 15%), current ratio 10.09 (avg: 2).